Prosecution Insights
Last updated: November 04, 2026
Application No. 18/889,671

Topical Pharmaceutical Compositions Comprising 2-[3-[4-Amino-3-(2-Fluoro-4-Phenoxy-Phenyl)-1H-Pyrazolo[3,4-D]Pyrimidin-1-YL]Piperidine-1-Carbonyl]-4,4-Dimethylpent-2-Enenitrile

Non-Final OA §112
Filed
Sep 19, 2024
Priority
Jan 08, 2020 — provisional 62/958,616 +3 more
Examiner
MERCIER, MELISSA S
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Principia Biopharma Inc.
OA Round
1 (Non-Final)
72%
Grant Probability
Favorable
1-2
OA Rounds
8m
Est. Remaining
78%
With Interview

Examiner Intelligence

Grants 72% — above average
72%
Career Allowance Rate
878 granted / 1217 resolved
+12.1% vs TC avg
Moderate +6% lift
Without
With
+5.7%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
41 currently pending
Career history
1265
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
43.9%
+3.9% vs TC avg
§102
14.8%
-25.2% vs TC avg
§112
23.4%
-16.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1217 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicants’ election of a cream in the reply filed on August 21, 2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Applicant has cancelled all non-elected claims. Status of Application Receipt of Applicant’s remarks and amended claims filed on August 21, 2026. Claims 72-82 are pending in this application. Claims 1-71 have been cancelled. All pending claims are under examination. Information Disclosure Statement Receipt of the Information Disclosure Statements (3) filed on February 13, 2026 is acknowledged. Signed copies are attached to this office action. Claim Objections Claim 72 is objected to because of the following informalities: the claim recites QS to 100 of purified water. In order to clarify the claim language, it is suggested Applicant amend the claim to recite “QS to 100% with purified water”. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 74 rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Regarding claim 74, the claim recites “at least about 0.5%”, no upper limit is recited. After a review of the specification, paragraph 0034 discloses Compound (I) or the pharmaceutically acceptable salt thereof is present in the topical pharmaceutical composition in an amount of about 0.1%, about 0.5%, about 2%, about 5%, or about 10%, by weight of the composition. Based on the specification, the upper limit of compound I is about 10%. Applicant’s attention is directed to MPEP 2163.05 III which discloses with respect to changing numerical range limitations, the analysis must take into account which ranges one skilled in the art would consider inherently supported by the discussion in the original disclosure. In the decision in In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976), the ranges described in the original specification included a range of "25%- 60%" and specific examples of "36%" and "50%." A corresponding new claim limitation to "at least 35%" did not meet the description requirement because the phrase "at least" had no upper limit and caused the claim to read literally on embodiments outside the "25% to 60%" range, however a limitation to "between 35% and 60%" did meet the description requirement. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 72-82 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 72 contains the trademark/trade names Pemulen TM polymer. Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph. See Ex parte Simpson, 218 USPQ 1020 (Bd. App. 1982). The claim scope is uncertain since the trademark or trade name cannot be used properly to identify any particular material or product. A trademark or trade name is used to identify a source of goods, and not the goods themselves. Thus, a trademark or trade name does not identify or describe the goods associated with the trademark or trade name. In the present case, the trademark/trade name is used to identify/describe, accordingly, the identification/description is indefinite. Regarding claim 77, the claim recites “substantially amorphous”, however, substantially, in this context is not defined by the instant specification. Applicant has not defined what amount of the compound has an amorphous structure. For purposes of prosecution, substantially is construed as any amount >50%. Proposed Examiner’s Amendment The Examiner proposes to amend the application as follows: Claim 72: In line 9, replace “Temulen TM polymer” with “copolymers of acrylic acid and C10-C30 alkyl acrylate crosslinked with allyl pentaerythritol” In line 12, replace “Q.S. to 100% of purified water” with “Q.S. to 100% with purified water” Claim 74: In line 2, replace “at least about 0.5% by weight” with “at least about 0.5% by weight to about 10% by weight”; Claim 77, In line 2, delete the term “substantially”. Allowable Subject Matter The claims are free of the art. The closest prior art is that of Goldstein (US 8,962,635) which discloses compounds and pharmaceutical salts of tyrosine kinase inhibitors and there treatment of diseases treatable by inhibition of tyrosine kinases such as cancer and inflammatory diseases such as arthritis, and the like (abstract). 2-(3-(4-amino-3-(2-fluoro-4-phenoxyphenyl)-1H- pyrazolo[3,4-d]pyrimidin-1-yl)piperidine-1-carbonyl)-4,4-dimethylpent-2-enenitrile is disclosed as a tyrosine kinase inhibitor compound (column 20, lines 30-33). Goldstein discloses pharmaceutical compositions can be administered by oral, systemic, or parenteral administration. He does not disclose the composition can be in the form of a cream or even administered topically. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to MELISSA S MERCIER whose telephone number is (571)272-9039. The examiner can normally be reached M-F 6:30 am to 4 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Robert A Wax can be reached at 571-272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MELISSA S MERCIER/ Primary Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Sep 19, 2024
Application Filed
Sep 09, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778918
PARENTERAL NUTRITION FORMULATION
3y 6m to grant Granted Nov 03, 2026
Patent 12778886
Oral Hydrogel Compositions and Uses
3y 6m to grant Granted Nov 03, 2026
Patent 12779034
SELF-SUSTAINED RELEASE IMMUNE ADJUVANT SUSPENSION, PREPARATION METHOD THEREFOR, AND USE THEREOF
3y 4m to grant Granted Nov 03, 2026
Patent 12779152
DRY POWDER FORMULATIONS OF EPINEPHRINE AND ASSOCIATED METHODS
2y 9m to grant Granted Nov 03, 2026
Patent 12773416
COMPOSITION, ARTICLE AND METHOD FOR AFFECTING A MAMMAL
4y 0m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
72%
Grant Probability
78%
With Interview (+5.7%)
2y 10m (~8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1217 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month